Treatment of Mycotic Aneurysms with Involvement of the Abdominal Aorta: Single-centre Experience in 44 Consecutive Cases  by Dubois, M. et al.
Eur J Vasc Endovasc Surg (2010) 40, 450e456Treatment of Mycotic Aneurysms with Involvement
of the Abdominal Aorta: Single-centre Experience in
44 Consecutive CasesM. Dubois a, K. Daenens a, S. Houthoofd a, W.E. Peetermans b, I. Fourneau a,*aDepartment of Vascular Surgery, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium
bDepartment of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
Submitted 10 May 2010; accepted 24 July 2010
Available online 16 August 2010KEYWORDS
Mycotic aneurysm;
Abdominal aorta* Corresponding author. Tel.: þ32 1
E-mail address: Inge.Fourneau@uz
1078-5884/$36 ª 2010 European Socie
doi:10.1016/j.ejvs.2010.07.017Abstract Objective: To review our management of mycotic aneurysms involving the abdom-
inal aorta over the past 2 decades to assess the safety and efficacy of in-situ and extra-
anatomic repair combined with antibiotic treatment.
Materials and methods: From March 1990 to August 2008, 44 patients with a mycotic aneu-
rysm involving the abdominal aorta were treated at our University Hospital. For all patients,
we recorded the aetiology, clinical findings and anatomic location of the aneurysm, as well as
bacteriology results, surgical and antibiotic therapy and morbidity and mortality.
Results: Twenty-one (47.7%) of the mycotic aneurysms had already ruptured at the time of
surgery. Free rupture was present in nine patients (20.5%). Contained rupture was observed
in 12 patients (27.3%).
Urgent surgery was performed in 18 cases (40.9%). Revascularisation was achieved by in-
situ reconstruction in 37 patients (84.1%), while extra-anatomic reconstruction was per-
formed in six patients (13.6%). One patient (2.3%) was treated with a combined in-situ and
extra-anatomic reconstruction. In one case (2.3%), endovascular aneurysm repair (EVAR)
was performed.
In-hospital mortality was 22.7%, 50% in the extra-anatomic reconstruction group and 18.9%
in the in-situ repair group. One-third (33.3%) of our patients, who presented with a ruptured
mycotic aneurysm died in the peri-operative period. This mortality was 13% in the patient-
group presenting with an intact aneurysm.
Of the 34 surviving patients, 12 patients (27.3% of surviving patients died after discharge
from our hospital. In half of these patients, an acute cardiac event was to blame. Three
patients (8%) showed re-infection after in-situ reconstruction.6 34 68 50; fax: þ32 16 34 68 52.
leuven.be (I. Fourneau).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Treatment of Mycotic Aneurysms in 44 Consecutive Cases 451Conclusion: Management of mycotic aortic aneurysms remains a challenging problem. The
results of surgery depend on many factors. In our experience, in-situ repair remains a feasible
and safe treatment option for patients who are in good general condition at the time of
surgery.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Cardiovascular risk-factors.
Cardiovascular risk-factors N % of total
Arterial systolic hypertension 20 45.5
Hyperlipidemia 12 27.3
History of CVA/TIA 4 9.1
Diabetes 11 25
Active smokers 18 40.9
Past smokers 7 15.9Introduction
Mycotic aneurysms were first described by Sir William Osler
in 1851 in a 30-year-old man with four aneurysms of the
aortic arch, arising as a complication of endocarditis.1 Since
there is no apparent association with fungal disease, the
term mycotic aneurysm has always been a source of
discussion among vascular surgeons. However, most authors
use the term ‘mycotic aneurysm’ to describe any aneurysm,
secondary to infection, regardless of its pathogenesis.
Infected aortic aneurysms remain quite infrequent. They
are reported at around 1% of all aortic aneurysms. They
occur all over the aorta, but nearly 50% are seen at the
infrarenal aorta. The juxtarenal or pararenal aorta is
involved in 25% of the cases.2
This article describes our experience with the treatment
of 44 patients with a mycotic aneurysm involving the
abdominal aorta in order to assess the safety and efficacy
of in-situ and extra-anatomic repair of mycotic aneurysms
in a single-centre.
Materials and methods
From March 1990 to August 2008, 44 patients with a mycotic
aneurysm involving the abdominal aorta were treated at
our University Hospital. We retrospectively analysed all
these patients. The diagnosis of mycotic aortic aneurysm
was established, based on the following criteria: (1)
symptoms of infection (fever, associated with abdominal or
back pain), (2) computed tomography (CT)-scan findings
(peri-aortic soft-tissue mass or oedema, rapid aneurysm
development and progression on sequential studies, peri-
aortic gas or gas within the aneurysm thrombus), (3) intra-
operative findings of inflammation and purulence and (4)
positive aneurysm wall culture. Other evidence such as
positive blood cultures and the presence of recent infection
or sepsis was also taken into account. For all patients, we
recorded the aetiology, clinical findings and anatomic
location of the aneurysm, as well as bacteriology results,
surgical and antibiotic therapy and morbidity and mortality.
The results are presented below.
Results
During this 18-year period, 38 men and 6 women were
treated, with a mean age of 67.3 years (range, 42e84
years).
Etiology
Fourteen patients (31.8%) had a proven history of infectious
or septic disease. Six of them (13.6%) had presented with
Salmonella enteritis weeks to months prior to surgery. Twopatients (4.6%) had presented with urosepsis. The other
patients presented with septic arthritis of the ankle joint
and concomitant pneumonia (n Z 1), spondylodiscitis on
L1eL2 level (n Z 1), calcaneal osteomyelitis (n Z 1),
cathetersepsis (n Z 1), sternitis post-cardiac surgery
(n Z 1) or pharyngitis (n Z 1). In the other patients, no
clear history of infectious disease could be retrieved.
However, an infectious episode presenting as malaise
remains often unrecognised in a retrospective analysis.
In 19 patients (43.2%) there were one or more indica-
tions of depressed immunocompetence. Of these patients,
11 (25%) had diabetes mellitus; 11 patients (25%) were on
corticosteroids, less than 3 months before surgery; and one
patient (2.3%) received chemotherapy for a non-Hodgkin
lymphoma.
The cardiovascular risk-factors are summarised in Table 1.
Symptoms and clinical findings
Forty-two patients (95.5%) were symptomatic. These
symptoms are summarised in Table 2. Thirty-four patients
(77.3%) complained of pain: 19 patients (43.2%) complained
of abdominal pain and 21 patients (47.7%) of back pain.
Six patients (13.6%) had pain in a hip and/or leg. Fever
was present in 20 cases (45.5%). Five patients (11.4%)
presented with weight loss and four patients (9.1%) had
gastro-intestinal symptoms, such as vomiting or diarrhoea.
Fourteen patients (31.8%) felt generally ill, without further
specification. Eight patients (18.2%) presented with
collapse and hypovolaemic shock, due to rupture. One
patient (2.3%) presented with a painful swelling on the base
of the right thoracic wall. One patient (2.3%) presented
with intermittent fever, chills, weight loss and nightly
sweating for several months. Six patients (13.6%) were
septic at presentation to our department.
Anatomic location
For this study, only mycotic aneurysms with involvement of
the abdominal aorta were included. The infrarenal aorta
was affected in 33 cases (75%). The iliac arteries were
involved in two cases (4.5%). A juxtarenal mycotic
Table 2 Symptoms and clinical findings.
Symptoms N Z 42 % of total
Pain 34 77.3
Abdominal pain 19 43.2
Back pain 21 47.7
Pain hip/leg 6 13.6
Fever 20 45.5
Weight loss 5 11.4
Gastro-intestinal:
vomiting, diarrhea, ileus
4 9.1
General discomfort 14 31.8
Collapse 8 18.2
Pulsatile mass 1 2.3
Melaena 1 2.3
Dysuria 1 2.3
Anemia 2 4.5
Elevated ESR 2 4.5
Edema leg 1 2.3
Haematoma leg 1 2.3
452 M. Dubois et al.aneurysm was present in nine patients (20.5%). Two
patients (4.5%) had a thoraco-abdominal mycotic
aneurysm.
Twenty-one (47.7%) of the mycotic aneurysms had
already ruptured at time of surgery. Free rupture was
present in nine patients (20.5%). Contained rupture was
observed in 12 patients (27.2%).
Surgical procedure
Urgent surgery was performed in 18 cases (40.9%). Revas-
cularisation was achieved by in-situ reconstruction in 37
patients (84.1%), while extra-anatomic reconstruction was
performed in six patients (13.6%). This type of repair was
preferred in patients in poor general condition at the time
of presentation. One patient (2.3%) was treated with
a combined in-situ and extra-anatomic reconstruction.
In thirty-two patients (72.7%), a trans-peritoneal
approach to the mycotic aneurysm was performed. In 11
patients (25%), the access was retroperitoneal. A retro-
peritoneal approach was preferred when re-implantation
or bypass of the visceral arteries was planned. In one case
(2.3%) endovascular aneurysm repair (EVAR) was
performed.
In the patients with an extra-anatomic reconstruction,
axillo-bifemoral reconstruction was performed in five cases
(83.3%). One patient (16.7%) underwent a bilateral axillo-
femoral bypass. In all of these patients, a resection of the
mycotic aneurysm and a transfixion of the aortic stump
with a non-absorbable running suture and coverage by
omentoplasty were carried out, followed by a debridement
of all surrounding infected tissue. This second-stage
procedure took place at a mean of 2 days (range, 1e3 days)
after the extra-anatomic reconstruction.
In the 36 patients with an in-situ repair, reconstruction
to the iliac arteries was performed in 16 patients (44.4%)
and to the femoral arteries in six patients (16.7%). Fourteenpatients (38.9%) were treated with an aorto-aortic tube
interposition. In 10 patients (27.8%), a Dacron graft was
used, while in 13 patients (36.1%), silver impregnated
Dacron graft was used. In 18 (78.3%)of these 23 patients,
treated with a prosthetic graft, the graft was soaked in
Rifampycin prior to implantation. A homograft was used in
eight cases (22.2%). In five patients (13.9%), an autologous
deep vein was used for in-situ reconstruction.
Visceral or renal arteries had to be re-implanted in seven
patients (15.9%), while in five patients (11.4%) a bypass to
the visceral or renal arteries was constructed. Resection of
the mycotic aneurysm and rigorous debridement of all
infected tissue was carried out in 43 patients (97.7%), and
healing was supported by an omentoplasty in 30 cases
(68.2%).
Four patients (9.1%) had concomitant abdominal proce-
dures. In one case, corporectomy and lateral fusion of
spondylodiscitis-infected vertebrae was performed.
Another patient underwent a left hemicolectomy for rectal
cancer, discovered during the vascular procedure. In one
patient, a cholecystectomy was performed because of
a synchronous necrotic cholecystitis. In one patient, left
colonic ischemia became apparent immediately after
resection and debridement of the mycotic aortic aneurysm.
Consequently, a left hemicolectomy was performed.
Bacteriology
Cultures from the aneurysmal content and the arterial wall
as well as blood cultures were obtained in all but two
patients. In 33 patients (78.6%), a bacterial species could
be identified. In nine patients (21.4%), cultures were
negative, probably due to antibiotic treatment prior to
surgery. In most patients (20 patients, 47.6%), a Gram-
negative species was identified. Several cultures yielded
multiple species. The isolated species are summarised in
Table 3.Antibiotic treatment
Thirty-eight patients (86.4%) were treated with antibiotics
peri-operatively and post-operatively. Immediately after
deep tissue cultures were taken, intravenous antibiotics
were administered empirically. If needed, this treatment
was adjusted later, according to culture results. Twenty
patients (45.5%) were treated with Beta-Lactam antibi-
otics. In 17 cases (38.6%), Quinolones were administered.
Vancomycin was used in 10 patients (22.7%). In 13 cases,
other agents were used. In 16 patients (36.4%), a certain
type of antibiotics was administered. Two antibiotics of
different classes were used in 13 patients (29.5%). Six
patients (13.6%) received three or more types of antibi-
otics. The mean duration of antibiotic treatment was 39.5
days (range, 7e81 days). The duration of antibiotic treat-
ment of each patient was influenced by the type of surgical
reconstruction. Whenever in-situ revascularisation with
a prosthetic graft was performed, antibiotics were given
for a longer period of time. In patients with a venous
reconstruction, antibiotics were stopped sooner, in the
absence of fever and clinical as well as biochemical signs of
infection.
Table 3 Micro-organisms cultured from specimens of the aneurysmal content and arterial wall of the mycotic aortic
aneurysm.
Micro-organism N % of total Gram stain
Salmonella species 13 29.5 e
Staphylococcus aureus 7 15.9 þ
MSSA 6 13.6 þ
MRSA 1 2.3 þ
Streptococcus pneumoniae 3 6.8 þ
Escherichia coli 3 6.8 e
Streptococcus viridans 2 4.5 þ
Streptococcus pyogenes 1 2.3 þ
Coagulase-negative Staphylococcus 1 2.3 þ
Bacteroides fragilis 1 2.3 e
Campylobacter jejuni 1 2.3 e
Klebsiella species 1 2.3 e
Enterobacter species 1 2.3 e
Pseudomonas aeruginosa 1 2.3 e
Acinetobacter species 1 2.3 e
Listeria monocytogenes 1 2.3 þ
Pseudodiphteroid bacillus 1 2.3 þ
Mycobacterium tuberculosis 1 2.3
Table 5 Complications after surgery for mycotic aortic
aneurysm.
Complications N (%)
Atrial fibrillation 6 (13.6)
Renal failure 10 (22.7)
Sepsis 8 (18.2)
Intestinal ischemia 2 (4.5)
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days). The mean stay at the intensive care unit was 12.4
days (range, 0e88 days).
Short-term outcome
In-hospital mortality was 22.7%. Thirty-day mortality was
18.2%. One patient died of hypovolaemic shock due to
rupture of the proximal anastomosis, 1 day after placing an
aorto-iliac graft. One patient died of a fulminant progres-
sive course of a previously known cancer. Two patients died
of respiratory failure. Six patients succumbed to sepsis.
One-third (33.3%) of our patients, who presented with
a ruptured mycotic aneurysm, free and/or contained, died
in the peri-operative period. This mortality was 13% in the
patient-group presenting with an intact aneurysm (Table 4).
Three (50%) of six patients with an extra-anatomical
reconstruction died in the peri-operative period, whereas 7
(18.9%) of 37 patients with an in-situ repair died during this
period.
General complications were seen in 26 patients (59.1%).
Twenty patients (45.5%) had local complications (Table 5).Table 4 Peri-operative mortality in relation to status of
perforation.
Status of
perforation
N (%) No. of in-hospital
deaths (%)
Rupture 21 (47.7) 7 (33.3)
Free 9 (20.5) 3 (33.3)
Contained 12 (27.3) 4 (33.3)
Intact 23 (52.3) 3 (13.0)
Totals 44 (100) 10 (22.7)Late-term outcome
The mean follow-up was 4.4 years (range, 40 dayse13
years). Four patients (9.1%) were lost to follow-up.
Of the 34 surviving patients, 12 patients (27.3%) died after
discharge fromour hospital. In half of these patients an acute
cardiac event was the cause of death (Table 6). The
remaining 22 patients are well, without signs of infection.
Three patients (8%) showed re-infection after in-situ
reconstruction. The first patient had an infrarenal Dacron
graft that was replaced by an autologous deep vein. In the
second patient, a new mycotic aneurysm on the implanted
homograft became apparent 39 days after initial surgery forRespiratory infection 6 (13.6)
Paraplegia 1 (2.3)
Decubitus 2 (4.5)
Local wound infection 5 (11.4)
Revision surgery 13 (29.5)
Bleeding 5 (11.4)
Graft occlusion 2 (4.5)
Peripheral ischemia 2 (4.5)
Perforated diverticulitis 1 (2.3)
Recurrent infection 2 (4.5)
Leakage intestinal
anastomosis
1 (2.3)
Chyle leakage 1 (2.3)
Table 6 Mortality after treatment of mycotic aortic
aneurysm.
Mortality N (%)
Overall 22 (50.0)
In-hospital 10 (22.7)
Late 12 (27.3)
Cardiac event 6 (13.6)
Cerebrovascular event 1 (2.3)
Respiratory infection 3 (6.8)
Sepsis 1 (2.3)
Unknown 1 (2.3)
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then replaced by an autologous venous graft. This graft
became infected and consequently ruptured and therefore
had to be replaced by an axillo-bifemoral graft, 10 days
later. One month later, this graft again became infected
and was replaced by a homograft from the ascending aorta
to the right femoral artery, together with a crossover to the
left femoral artery. Two years later the entire homograft
was degenerated with considerable aneurismal and
thrombus formation. This graft was replaced by a pros-
thetic graft. One month later this patient died of acute
myocardial infarction. One patient was re-admitted to our
hospital with an acute abdomen and septic shock, 73 days
after initial treatment. An urgent laparotomy was per-
formed, with drainage of more than 5 l of pus, probably
originating from an infection of the aorto-iliac prosthetic
graft. This patient died peri-operatively, due to septic
shock.
Discussion
Management of mycotic aortic aneurysms remains a chal-
lenging problem. The results of surgery depend on many
factors. The type of aneurysm, the location, the mode of
presentation, the responsible micro-organism, the antibi-
otic treatment and the type of surgical treatment are all
important issues. It is well known that patients with
a mycotic aortic aneurysm are usually in a poor general
condition, often immunosuppressed in one way or another,
as is also demonstrated in our study group.
In literature, overall mortality varies between 10% and
60%.3-13 Hsu et al. identified non-Salmonella infection and
advanced age as risk-factors for operative mortality.12
Fillmore et al. determined that sepsis is the leading cause
of death for surgical infected aneurysm patients and that
a combination of host- and infection-specific variables may
be more predictive of outcome than any single factor.10
Olderich et al. defined five independent variables associ-
ated with operative mortality: extensive peri-aortic infec-
tion, female sex, Staphylococcus aureus infection,
aneurysm rupture and supra-renal location. In accordance
with other authors8,11 and our earlier experience,14
Staphylococcus aureus and Salmonella species were the
most common micro-organisms cultured from our intra-
operative specimens. In the large series published by Mu¨ller
et al. (n Z 33), the operative mortality for rupture was
63%, compared to zero-mortality for intact aneurysms.8 Thenegative effect of rupture on survival is also clear from our
own earlier experience where the mortality rate of 19%
increased to 40% in case of rupture.14 This is also demon-
strated in the current series (Table 4). An early diagnosis is
therefore critical with regard to early outcome.
The optimal surgical management, especially of
infrarenal mycotic aortic aneurysms, remains controversial
in many ways. From a classic surgical point of view, extra-
anatomic reconstruction has to be considered as treatment
of choice for aortic sepsis, in order to avoid the use of
prosthetic grafts in an infected environment.5,13 This
approach has the theoretical advantage of a reconstruction
through a plane remote from the infection. However,
patency rates of axillo-bifemoral bypasses are known to be
poor and aortic stump bleeding and rupture have been well
described.5,6 Alternatively, other authors have published on
in-situ reconstruction.3e5,8,9,11,12 In order to reduce the risk
of re-infection, a wide and extensive debridement of all
infected tissue and a resection of the aorta back to the
healthy, non-infected wall is mandatory. After reconstruc-
tion, the graft should be covered with non-infected viable
tissue. We preferred the use of a pedicled flap of greater
omentum. The gratifying effect of an omental flap is
supposedly due to increased blood supply to the infected
area which, in turn, intensifies inflammatory cell infiltra-
tion and increases tissue concentrations of antibiotics. In
our series, we observed three cases of re-infection (8%)
after in-situ reconstruction. The vast majority of prosthetic
grafts we implanted in this series were rifampicinsoaked
and/or silver coated. Rifampicin is active against Staphy-
lococci and therefore the use of such impregnation seems
logical, if used in an infected environment. However, the
results of prophylactic antibiotic impregnated grafts, not
used for infected aneurysms, failed to show any ben-
efit.15e18 Favourable results with cryopreserved arterial
homografts have been reported.19e23 Lese`che et al.
reported no persistent or recurrent infection in their
prospective series of 28 consecutive patients with an
infected prosthetic graft or mycotic aortic aneurysm.
Limited aneurismal deterioration of the cryopreserved
allograft occurred in three (13%) of their patients. They
reported a 100% limb salvage rate. The 3-year primary and
secondary allograft patency rates were 81% and 96%,
respectively. The overall treatment-related mortality rate
was 17.8% (20% for primary aortic infection).19 In a multi-
centric study, reported by Verhelst et al., the incidence of
homograft rupture was 41% in case of virulent infection.24
In our population, we observed one case of aneurismal
degeneration of a homograft. At our institution, there is
considerable experience with the use of autologous femoral
vein in the treatment of graft infection.25,26 The advantage
of this venous graft is its resistance to infection and
aneurismal dilatation.25e29 However, the procurement of
the vein is time consuming and therefore contra-indicated
in emergency setting. In this series, we treated five
patients with an autologous femoral vein. Two patients died
in the early post-operative period, one due to cancer and
the other succumbed to respiratory failure. The three
surviving patients are doing well, without signs of recurrent
infection or graft failure.
Endovascular repair of atherosclerotic thoracic and
abdominal aneurysms (EVAR) is well established. However,
Treatment of Mycotic Aneurysms in 44 Consecutive Cases 455placing an endovascular graft in an infected area remains
counter-intuitive, because resection of the mycotic aortic
aneurysm and debridement of all infected tissue are
cornerstones of open surgery. Semba et al. were the first to
report successful treatment with EVAR in three patients
with mycotic aneurysms.31 Several subsequent reports
suggest that EVAR provides a viable, less invasive alterna-
tive in the management of mycotic aortic aneurysms, with
favourable results.30,32e35 Kan et al. performed a system-
atic review of the outcome after endovascular stent graft
treatment for mycotic aortic aneurysms. Their life-table
analysis showed that the 30-day survival rate was
89.6%  4.4% and the 2-year survival rate was 82.2%  5.8%.
Their univariate analysis revealed that age 65 or older,
ruptured aneurysms (including those with aorto-enteric and
aorto-bronchial fistulas), and fever at the time of operation
are significant parameters related to the incidence of
persistent infection in EVAR treatment for mycotic aortic
aneurysms. However, by multivariate logistic regression
analysis, the only significant predictors identified were
rupture of aneurysm and fever.30 In our series, we treated
one patient with EVAR because of many co-morbidities of
the patient. Two years post-operatively, he is still doing
well without signs of infection of the graft. Further
research is required to establish the role of EVAR in the
treatment of mycotic aortic aneurysms.
Conflict of Interest
None.
Acknowledgements
The authors want to express their gratitude to Prof. Dr. A.
Nevelsteen, who performed most of these procedures and
initiated the idea for this study, but died in December 2009,
before this article was completed.
References
1 Osler W. The Gulstonian lectures on malignant endocarditis.
Br Med J 1885;1:467e70.
2 Miller DV, Oderich GS, Aubry MC, Panneton JM, Edwards WD.
Surgical pathology of infected aneurysms of the descending
thoracic and abdominal aorta: clinicopathologic correlations in
29 cases (1976 to 1999). Hum Pathol 2004;35(35):1112e20.
3 Reddy DJ, Shepard AD, Evans JR, Wright DJ, Smith RF, Ernst CB.
Management of infected aortoiliac aneurysms. Arch Surg 1991;
126(7):873e8.
4 Fichelle JM, Tabet G, Cormier P, Farkas JC, Laurian C, Gigou F,
et al. Infected infra-renal aortic aneurysms: when is in situ
reconstruction safe? J Vasc Surg 1993;17(4):635e45.
5 Pasic M, Carrel T, Tonz M, Vogt P, von Segesser L, Turina M.
Mycotic aneurysm of the abdominal aorta: extra-anatomic
versus in situ reconstruction. Cardiovasc Surg 1993;1(1):48e52.
6 Moneta GL, Taylor Jr LM, Yeager RA, Edwards JM, Nicoloff AD,
McConnell DB, et al. Surgical treatment of infected aortic
aneurysm. Am J Surg 1998;175(5):396e9.
7 Ihya A, Chiba Y, Kimura T, Morioka K, Uesaka T. Surgical
outcome of infectious aneurysms of the abdominal aorta with or
without SIRS. Cardiovasc Surg 2001;9:436e40.
8 Muller BT, Wegener OR, Grabitz K, Pillny M, Thomas L,
Sandmann W. Mycotic aneurysms of the thoracic andabdominal aorta and iliac arteries: experience with anatomic
and extraanatomic repair in 33 cases. J Vasc Surg 2001;33:
106e13.
9 Oderich GS, Panneton JM, Bower TC, Cherry Jr KJ, Rowland CM,
Noel AA, et al. Infected aortic aneurysms: aggressive presen-
tation, complicated early outcome, but durable results. J Vasc
Surg 2001;34(5):900e8.
10 Fillmore AJ, Valentine RJ. Surgical mortality in patients with
infected aortic aneurysms. J Am Coll Surg 2003;196:435e41.
11 Kyriakides C, Kan Y, Kerle M, Cheshire NJ, Mansfield AO,
Wolfe JH. 11-year experience with anatomical and extra-
anatomical repair of mycotic aortic aneurysms. Eur J Vasc
Endovasc Surg 2004;27(6):585e9.
12 Hsu RB, Chen RJ, Wang SS, Chu SH. Infected aortic aneurysms:
clinical outcome and risk factor analysis. J Vasc Surg 2004;40:
30e5.
13 Woon CYL, Sebastian MG, Tay KH, Tan SG. Extra-anatomic
revascularization and aortic exclusion for mycotic aneurysms of
the infrarenal aorta and iliac arteries in an Asian population.
Am J Surg 2008;195:66e72.
14 Nevelsteen A, Daenens K, Fourneau I, Coppin V. Ruptured
mycotic aortic aneurysm. In: Branchereau A, Jacobs M, editors.
Unexpected challenges in vascular surgery. Malden (MA):
Blackwell Publishing; 2005. p. 129e42.
15 Earnshaw JJ. The current role of rifampicin-impregnated grafts:
pragmatism versus science. Eur J Vasc Endovasc Surg 2000;20:
409e12.
16 Earnshaw JJ, Whitman B, Heather BP. Two-year results of
a randomized controlled trial of rifampicin-bonded extra-
anatomic dacron grafts. Br J Surg 2000;87:758e9.
17 Braithwaite BD, Davies B, Heather BP, Earnshaw JJ. Early results
of a randomized trial of rifampicin-bonded dacron grafts for
extra-anatomic vascular reconstruction. Br J Surg 1998;85:
1378e81.
18 Gupta AK, Bandyk DF, Johnson BL. In situ repair of mycotic
abdominal aortic aneurysms with rifampin-bonded gelati-
nimpregnated dacron grafts: a preliminary case report. J Vasc
Surg 1996;24:472e6.
19 Lese`che G, Castier Y, Petit MD, Bertrand B, Kitzis M, Mussot S,
et al. Long-term results of cryopreserved arterial allograft
reconstruction in infected prosthetic grafts and mycotic aneu-
rysms of the abdominal aorta. J Vasc Surg 2001;34(4):616e22.
20 Vogt PR, Brunner-LaRocca HP, Lachat M, Ruef C, Turina MI.
Technical details with the use of cryopreserved arterial allo-
grafts for aortic infection: influence on early and midterm
mortality. J Vasc Surg 2002;35(1):80e6.
21 Vogt P, Pasic M, von Segesser L, Carrel T, Turina M. Cry-
opreserved aortic homograft for mycotic aneurysm. J Thorac
Cardiovasc Surg 1995;109(3):589e91.
22 Vogt PR, Brunner-La Rocca HP, Carrel T, von Segesser LK,
Ruef C, Debatin J, et al. Cryopreserved arterial allografts in the
treatment of major vascular infection: a comparison with
conventional surgical techniques. J Thorac Cardiovasc Surg
1998;116(6):965e72.
23 Kieffer E, Bahnini A, Koskas F, Ruotolo C, Le Blevec D,
Plissonnier D. In situ allograft replacement of infected
infrarenal aortic prosthetic grafts: results in forty-three
patients. J Vasc Surg 1993;17(2):349e55.
24 Verhelst R, Lacroix V, Vraux H, Lavigne JP, Vandamme H,
Limet R, et al. Use of cryopreserved arterial homografts for
management of infected prosthetic grafts: a multicentric study.
Ann Vasc Surg 2000;14:602e7.
25 Nevelsteen A, Lacroix H, Suy R. Autogenous reconstruction with
the lower extremity deep veins: an alternative treatment of
prosthetic infection after reconstructive surgery for aortoiliac
disease. J Vasc Surg 1995;22:129e34.
26 Daenens K, Fourneau I, Nevelsteen A. Ten-year experience in
autogenous reconstruction with the femoral vein in the
456 M. Dubois et al.treatment of aortofemoral prosthetic infection. Eur J Vasc
Endovasc Surg 2003;25(3):240e5.
27 Franke S, Voit R. The superficial femoral vein as arterial
substitute in infections of the aortoiliac region. Ann Vasc Surg
1997;11(4):406e12.
28 Brown Jr PM, Kim VB, Lalikos JF, Deaton DH, Bogey WM,
Powell CS. Autologous superficial femoral vein for aortic recon-
struction in infected fields. Ann Vasc Surg 1999;13(1):32e6.
29 Benjamin ME, Cohn Jr EJ, Purtill WA, Hanna DJ, Lilly MP,
Flinn WR. Arterial reconstruction with deep leg veins for the
treatment of mycotic aneurysms. J Vasc Surg 1999;30:1004e15.
30 Kan CD, Lee HL, Yang YJ. Outcome after endovascular stent
graft treatment for mycotic aortic aneurysm: a systematic
review. J Vasc Surg 2007;46(5):906e12.
31 Semba CP, Sakai T, Slonim SM, Razavi MK, Kee ST, Jorgensen MJ,
et al. Mycotic aneurysms of the thoracic aorta: repair with useof endovascular stent-grafts. J Vasc Interv Radiol 1998;9(1 Pt
1):33e40.
32 Jones KG, Bell RE, Sabharwal T, Aukett M, Reidy JF, Taylor PR.
Treatment of mycotic aortic aneurysms with endoluminal
grafts. Eur J Vasc Endovasc Surg 2005;29(2):139e44.
33 Smith JJ, Taylor PR. Endovascular treatment of mycotic
aneurysms of the thoracic and abdominal aorta: the need
for level I evidence. Eur J Vasc Endovasc Surg 2004;27(6):
569e70.
34 Ting AC, Cheng SW, Ho P, Poon JT. Endovascular stent graft
repair for infected thoracic aortic pseudoaneurysmsea durable
option? J Vasc Surg 2006;44(4):701e5.
35 Clough RE, Black SA, Lyons OT, Zayed HA, Bell RE, Carrell T,
et al. Is endovascular repair of mycotic aortic aneurysms
a durable treatment option? Eur J Vasc Endovasc Surg 2009;37:
407e12.
